UCB (STU:UNC) Total Receivables: €1,611 Mil (As of Dec. 2025)


STU:UNC UCB SA STU:UNC
89 GF Score
Price €250.00
GF Value €211.18
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is UCB Total Receivables?

UCB STU:UNC -1.46% 89 Total Receivables is €1,611 Mil as of Dec. 2025. GuruFocus rates STU:UNC with a GF Score™ of 89/100 and a GF Value™ of €211.18 (Modestly Overvalued). The stock has 2 warning signs investors should review.

UCB's Total Receivables for the quarter that ended in Dec. 2025 was €1,611 Mil.

UCB Total Receivables Historical Data

* Premium members only.

The historical data trend for UCB's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Total Receivables Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,041.00 879.00 1,036.00 1,310.00 1,611.00

UCB Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,036.00 1,369.00 1,310.00 1,848.00 1,611.00
STU:UNC
89GF Score
UCB SA STU:UNC
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €1,611 Mil mean?
UCB (STU:UNC) has a Total Receivables of €1,611 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on UCB and its competitors.
Is UCB's Total Receivables too high?
UCB's current Total Receivables is €1,611 Mil. Overall, UCB has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Total Receivables compare to VRTX and REGN?
UCB's Total Receivables of €1,611 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on UCB and its competitors. UCB's current Total Receivables is €1,611 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €211.18, compared to a current price of €250.00 — trading 18.4% above its estimated fair value. The current Total Receivables is €1,611 Mil. UCB's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For UCB (STU:UNC), the current Total Receivables is €1,611 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €250.00 is trading 18.4% above its estimated GF Value™ of €211.18. GuruFocus considers UCB to be Modestly Overvalued.

Key valuation signals for STU:UNC:

  • Total Receivables: €1,611 Mil
  • GF Value™: €211.18 vs. price of €250.00 (18.4% above fair value)
  • GF Score™: 89/100 with 2 warning signs

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
89GF Score

Get the complete analysis for STU:UNC

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€250.00
Price
€211.18
GF Value